EURI B Stock Overview
Manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
European Institute of Science AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.64 |
| 52 Week High | SEK 18.00 |
| 52 Week Low | SEK 1.60 |
| Beta | 2.05 |
| 11 Month Change | 70.59% |
| 3 Month Change | 8.92% |
| 1 Year Change | -71.36% |
| 33 Year Change | -96.51% |
| 5 Year Change | -98.64% |
| Change since IPO | -99.83% |
Recent News & Updates
Shareholder Returns
| EURI B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 54.7% | -2.4% | -4.3% |
| 1Y | -71.4% | 18.0% | 12.6% |
Return vs Industry: EURI B underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: EURI B underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| EURI B volatility | |
|---|---|
| EURI B Average Weekly Movement | 32.2% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: EURI B's share price has been volatile over the past 3 months.
Volatility Over Time: EURI B's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 2 | Kirstin Kriz | www.euris.org |
European Institute of Science AB (publ) manufactures and sells diagnostic assays for the clinical laboratory and point-of-care settings, and point-of-care instrumentation for diagnostic applications in Sweden. It primarily focuses on the diagnostic assays and instrumentation for canine, feline, and equine animals. The company’s products include TurboReader point-of-care instruments that performs measurements using disposable cuvettes; Canine C-Reactive (CRP) TurboReader assays for the quantitative determination of Canine CRP in dog serum or plasma; Feline Hp (Haptoglobin) TurboReader assay for determining Hp in cat serum or plasma; Feline SAA TurboReader assay for the determination of serum amyloid A (SAA) in cat serum or plasma; and Equine SAA TurboReader assay for determining SAA in horse serum or plasma.
European Institute of Science AB (publ) Fundamentals Summary
| EURI B fundamental statistics | |
|---|---|
| Market cap | SEK 2.67m |
| Earnings (TTM) | -SEK 2.65m |
| Revenue (TTM) | SEK 765.87k |
3.5x
P/S Ratio-1.0x
P/E RatioIs EURI B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EURI B income statement (TTM) | |
|---|---|
| Revenue | SEK 765.87k |
| Cost of Revenue | SEK 347.41k |
| Gross Profit | SEK 418.45k |
| Other Expenses | SEK 3.07m |
| Earnings | -SEK 2.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.61 |
| Gross Margin | 54.64% |
| Net Profit Margin | -346.31% |
| Debt/Equity Ratio | 0% |
How did EURI B perform over the long term?
See historical performance and comparison